ENLV

+ Watchlist + Portfolio

Enlivex Therapeutics Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.73
52-Week Range: $1.46 – $27.15
Market Cap: $26.23M
P/E (TTM): 0.00
EPS (TTM): 331.39
Dividend Yield: —

Advanced Metrics

Price/Book: 0.01
PEG Ratio: —
Return on Equity: 126.17%
Return on Assets: -0.80%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 193.24
Debt/Equity: 0.00
Total Debt: $641.00K
Free Cash Flow: $-1.74B
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $18.62M

ENLV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$18.69M	$19.01M	$10.62M	$9.20M
Selling, General & Admin	$6.70M	$5.23M	$4.81M	$5.68M
Operating Expenses	$25.80M	$25.15M	$14.93M	$15.00M
Operating Income	-$25.80M	-$25.15M	-$14.93M	-$15.00M
EBITDA	-$25.02M	-$24.32M	-$14.39M	-$14.67M
Pretax Income	-$31.06M	-$29.07M	-$15.01M	$1.62B
Income Tax	—	$0.00	$0.00	$382.65M
Net Income	-$31.06M	-$29.07M	-$15.01M	$1.24B
Diluted EPS	-1.69	-1.56	-0.73	—
Diluted Shares	18.39M	18.57M	20.51M	—

ENLV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$49.95M	$813.00K	$3.30M	$1.89M
Receivables	$647.00K	$229.00K	$1.42M	$510.00K
Current Assets	$52.33M	$33.76M	$25.99M	$1.74B
Total Assets	$67.64M	$36.83M	$27.69M	$2.33B
Current Liabilities	$6.61M	$6.06M	$3.80M	$9.02M
Total Debt	$4.85M	$1.03M	$534.00K	$641.00K
Total Liabilities	$10.80M	$6.75M	$4.10M	$392.05M
Retained Earnings	-$83.03M	-$112.09M	-$127.11M	$1.11B
Shareholders' Equity	$56.84M	$30.08M	$23.59M	$1.93B
Working Capital	$45.72M	$27.70M	$22.19M	$1.73B

ENLV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.95M	-$23.52M	-$13.01M	-$10.42M
Capital Expenditure	-$8.12M	-$236.00K	-$103.00K	-$68.00K
Free Cash Flow	-$32.08M	-$23.76M	-$13.11M	-$10.48M
Depreciation & Amortisation	$777.00K	$835.00K	$545.00K	$332.00K
Stock-Based Compensation	$2.71M	$1.95M	$2.06M	$1.78M
Investing Cash Flow	$62.52M	-$25.97M	$9.06M	-$1.32M
Financing Cash Flow	$150.00K	$360.00K	$6.45M	$10.38M
Net Change in Cash	$38.72M	-$49.13M	$2.50M	-$1.36M

ENLV Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.42M	$2.55M	$2.14M	$1.48M	$3.03M
Selling, General & Admin	$1.96M	$954.00K	$937.00K	$1.07M	$2.72M
Operating Expenses	$4.88M	$3.50M	$3.08M	$2.56M	$5.86M
Operating Income	-$4.88M	-$3.50M	-$3.08M	-$2.56M	-$5.86M
EBITDA	-$4.84M	-$3.41M	-$2.99M	-$2.48M	-$5.79M
Pretax Income	-$5.18M	-$3.45M	-$1.87M	-$2.21M	$1.63B
Net Income	-$5.18M	-$3.45M	-$1.87M	-$2.21M	$1.24B
Diluted EPS	—	-0.15	-0.08	-0.09	—
Diluted Shares	—	23.76M	23.86M	24.05M	—

ENLV Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Cash & Equivalents	$3.30M	$2.05M	$1.89M	$4.08M	$1.89M
Receivables	$1.42M	$1.23M	$1.01M	$759.00K	$510.00K
Current Assets	$25.99M	$22.65M	$21.32M	$19.50M	$1.74B
Total Assets	$27.69M	$24.04M	$22.60M	$20.94M	$2.33B
Current Liabilities	$3.80M	$3.14M	$3.33M	$3.03M	$9.02M
Total Debt	$534.00K	$503.00K	$480.00K	$701.00K	$641.00K
Total Liabilities	$4.10M	$3.41M	$3.54M	$3.46M	$392.05M
Retained Earnings	-$127.11M	-$130.56M	-$132.43M	-$134.63M	$1.11B
Shareholders' Equity	$23.59M	$20.63M	$19.05M	$17.48M	$1.93B
Working Capital	$22.19M	$19.50M	$18.00M	$16.47M	$1.73B

ENLV Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Operating Cash Flow	-$4.08M	-$4.62M	-$1.20M	-$1.97M	-$2.63M
Capital Expenditure	-$35.00K	-$32.00K	-$7.00K	-$21.00K	-$8.00K
Free Cash Flow	-$4.12M	-$4.66M	-$1.21M	-$1.99M	-$2.63M
Depreciation & Amortisation	$36.00K	$90.00K	$85.00K	$81.00K	$76.00K
Stock-Based Compensation	$917.00K	$293.00K	$295.00K	$280.00K	$915.00K
Investing Cash Flow	$3.36M	$3.17M	$1.07M	$3.81M	-$9.38M
Financing Cash Flow	$1.26M	$197.00K	$0.00	$352.00K	$9.83M
Net Change in Cash	$535.00K	-$1.25M	-$129.00K	$2.20M	-$2.17M

Market Snapshot

About

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing therapies to reprogram immune cells for treatment of life-threatening conditions. The company's lead product candidate, Allocetra, is an off-the-shelf cell therapy designed to restore immune system balance in patients with severe conditions like sepsis and acute respiratory distress syndrome. Enlivex's approach involves using early apoptotic cells to modulate the immune response. The company is conducting clinical trials in multiple indications including COVID-19 complications.